ArticleGland surgery2025
The development and validation of a tumor-specific death predictive nomogram in patients with ovarian cancer: a cohort study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer has a high mortality rate. Accurate identification of risk factors for mortality is crucial to improve treatment strategies. Regretfully, prognostication tools are limited. In recent years, quantitative parameters of contrast enhanced ultrasound have shown economic, reproducible, and highly accurate advantages in predicting the prognosis of ovarian cancer patients. The purpose of this study was to develop a nomogram prediction model for the oncological outcome of patients with ovarian cancer based on quantitative parameters of contrast-enhanced ultrasound. Methods: Data from 357 patients with ovarian cancer admitted to The Fourth People's Hospital of Zhenjiang from January 2018 to December 2019 were retrospectively collected and constructed the training set. Data from 153 cases admitted to The People's Hospital of Zhaoyuan during the same period were collected and constructed the validation set. All patients were treated with primary cytoreductive surgery, and were followed up for 5 years after surgery. The differences in clinical characteristics and quantitative parameters of contrast-enhanced ultrasound were compared between patients who passed away within 5 years and those which did not. Results: Peak systolic velocity (PSV), stage III, poor differentiation, and ascites were independent risk factors for tumor-specific mortality in patients with ovarian cancer, with their relative risk being 2.011 (95% confidence interval: 1.680-2.407), 13.480 (95% confidence interval: 4.540-40.022), 2.997 (95% confidence interval: 1.206-7.452), and 2.997 (95% confidence interval: 1.206-7.452), respectively. Time to peak (TTP) was a protective factor of tumor-specific mortality in patients with ovarian cancer, with a relative risk of 0.800 (95% confidence interval: 0.731-0.875). The area under the receiver operating characteristic (ROC) curve in the training set was 0.948 (95% confidence interval: 0.926-0.969), and the area under the ROC curve in the validation set was 0.860 (95% confidence interval: 0.802-0.917). Conclusions: The nomogram prediction model for prognosis of patients with ovarian cancer based on quantitative parameters of contrast-enhanced ultrasound has good efficacy and reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.